VEGF-mediated tight junctions pathological fenestration enhances doxorubicin-loaded glycolipid-like nanoparticles traversing BBB for glioblastoma-targeting therapy

References

• Argaw AT, Gurfein BT, Zhang Y, et al. (2009). VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. P Natl Acad Sci USA 106:1977–82.
   PubMed Web of Science ®Google Scholar
• Breier G, Damert A, Blum S, et al. (1998). The role of vascular endothelial growth factor in tumor angiogenesis. Springer US 9:305–18.
   Google Scholar
• Chen J, Cun X, Ruan S, et al. (2015). Glioma cell-targeting doxorubicin delivery and redox-responsive release using angiopep-2 decorated carbonaceous nanodots. RSC Adv 5:57045–9.
   Web of Science ®Google Scholar
• Chen YC, Chiang CF, Chen LF, et al. (2014). Polymersomes conjugated with des-octanoyl ghrelin and folate as a BBB-penetrating cancer cell-targeting delivery system. Biomaterials 35:4066–81.
   PubMed Web of Science ®Google Scholar
• Claudio L. (1995). Ultrastructural features of the blood-brain barrier in biopsy tissue from Alzheimer's disease patients. Acta Neuropathol 91:6–14.
   Web of Science ®Google Scholar
• Daneman R. (2012). The blood-brain barrier in health and disease. Ann Neurol 72:648–72.
   PubMed Web of Science ®Google Scholar
• Feng S, Huang Y, Chen Z. (2011). Does VEGF secreted by leukemic cells increase the permeability of blood-brain barrier by disrupting tight-junction proteins in central nervous system leukemia? Med Hypotheses 76:618–21.
   PubMed Web of Science ®Google Scholar
• Greenberg DA, Jin K. (2005). From angiogenesis to neuropathology. Nature 438:954–9.
   PubMed Web of Science ®Google Scholar
• Hu YW, Du YZ, Liu N, et al. (2015). Selective redox-responsive drug release in tumor cells mediated by chitosan based glycolipid-like nanocarrier. J Control Release 206:91–100.
   PubMed Web of Science ®Google Scholar
• Huang R, Ke W, Han L, et al. (2011a). Targeted delivery of chlorotoxin-modified DNA-loaded nanoparticles to glioma via intravenous administration. Biomaterials 32:2399–406.
   PubMed Web of Science ®Google Scholar
• Huang S, Li J, Han L, et al. (2011b). Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma. Biomaterials 32:6832–8.
   PubMed Web of Science ®Google Scholar
• Huang S, Shao K, Liu Y, et al. (2013). Tumor-targeting and microenvironment-responsive smart nanoparticles for combination therapy of antiangiogenesis and apoptosis. ACS Nano 7:2860–71.
   PubMed Web of Science ®Google Scholar
• Jain RK, di Tomaso E, Duda DG, et al. (2007). Angiogenesis in brain tumours. Nat Rev Neurosci 8:610–22.
   PubMed Web of Science ®Google Scholar
• Jiao X, He P, Li Y, et al. (2015). The role of circulating tight junction proteins in evaluating blood brain narrier disruption following intracranial hemorrhage. Dis Markers 11:1–12.
   Web of Science ®Google Scholar
• Juillerat-Jeanneret L. (2008). The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles? Drug Discov Today 13:1099–106.
   PubMed Web of Science ®Google Scholar
• Kirk J, Plumb J, Mirakhur M, et al. (2003). Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination. J Pathol 201:319–27.
   PubMed Web of Science ®Google Scholar
• Lafuente JV, Argandona EG, Mitre B. (2006). VEGFR-2 expression in brain injury: its distribution related to brain-blood barrier markers. J Neural Transm (Vienna) 113:487–96.
   PubMed Web of Science ®Google Scholar
• Li J, Yang H, Zhang Y, et al. (2015). Choline derivate-modified doxorubicin loaded micelle for glioma therapy. ACS Appl Mater Interfaces 7:21589–601.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang R, Lu Z, et al. (2016). Microenvironment-responsive three-pronged approach breaking traditional chemotherapy to target cancer stem cells for synergistic inoperable large tumor therapy. Small 12:5516–23.
   PubMed Web of Science ®Google Scholar
• Lin T, Zhao P, Jiang Y, et al. (2016). Blood-brain-barrier-penetrating albumin nanoparticles for biomimetic drug delivery via albumin-binding protein pathways for antiglioma therapy. ACS Nano 10:9999–10012.
   PubMed Web of Science ®Google Scholar
• Liu G, Tsai HI, Zeng X, et al. (2017). Phosphorylcholine-based stealthy nanocapsules enabling tumor microenvironment-responsive doxorubicin release for tumor suppression. Theranostics 7:1192–203.
   PubMed Web of Science ®Google Scholar
• Liu N, Tan Y, Hu Y, et al. (2016). A54 peptide modified and redox-responsive glucolipid conjugate micelles for intracellular delivery of doxorubicin in hepatocarcinoma therapy. ACS Appl Mater Interfaces 8:33148–56.
   PubMed Web of Science ®Google Scholar
• Liu Y, Ran R, Chen J, et al. (2014). Paclitaxel loaded liposomes decorated with a multifunctional tandem peptide for glioma targeting. Biomaterials 35:4835–47.
   PubMed Web of Science ®Google Scholar
• Maletínská L, Blakely EA, Bjornstad KA, et al. (2000). Human glioblastoma cell lines: levels of low-density lipoprotein receptor and low-density lipoprotein receptor-related protein. Cancer Res 60:2300–3.
   PubMed Web of Science ®Google Scholar
• Martíncarbonero L, Palacios R, Valencia E, et al. (2008). Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin. Clin Infect Dis 47:410–17.
   PubMed Web of Science ®Google Scholar
• Meng TT, Liu JW, Wen LJ, et al. (2016). Multi-cycle chemotherapy with the glycolipid-like polymeric micelles evade cancer stem cell enrichment in breast cancer therapy. Oncotarget 7:72978–89.
   PubMed Web of Science ®Google Scholar
• Miao D, Jiang M, Liu Z, et al. (2014). Co-administration of dual-targeting nanoparticles with penetration enhancement peptide for antiglioblastoma therapy. Mol Pharmaceutics 11:90–101.
   PubMed Web of Science ®Google Scholar
• Mollard S, Fanciullino R, Giacometti S, et al. (2016). In vivo bioluminescence tomography for monitoring breast tumor growth and metastatic spreading: comparative study and mathematical modeling. Sci Rep 6:36173–82.
   PubMed Web of Science ®Google Scholar
• Ng KE, Amin MCIM, Katas H, et al. (2016). pH-responsive triblock copolymeric micelles decorated with a cell-penetrating peptide provide efficient doxorubicin delivery. Nanoscale Res Lett 11:539–51.
   PubMed Web of Science ®Google Scholar
• Ohtsuki S, Sato S, Yamaguchi H, et al. (2007). Exogenous expression of claudin-5 induces barrier properties in cultured rat brain capillary endothelial cells. J Cell Physiol 210:81–6.
   PubMed Web of Science ®Google Scholar
• Qin Y, Chen W, Liu B, et al. (2017). MiR-200c inhibits the tumor progression of glioma via targeting moesin. Theranostics 7:1663–73.
   PubMed Web of Science ®Google Scholar
• Schneider SW, Ludwig T, Tatenhorst L, et al. (2004). Glioblastoma cells release factors that disrupt blood-brain barrier features. Acta Neuropathol 107:272–6.
   PubMed Web of Science ®Google Scholar
• Siedlecki J, Wertheimer C, Wolf A, et al. (2017). Combined VEGF and PDGF inhibition for neovascular AMD: anti-angiogenic properties of axitinib on human endothelial cells and pericytes in vitro. Graefes Arch Clin Exp Ophthalmol 255:963–72.
   PubMed Web of Science ®Google Scholar
• Tajes M, Ramos-Fernandez E, Weng-Jiang X, et al. (2014). The blood-brain barrier: structure, function and therapeutic approaches to cross it. Mol Membr Biol 31:152–67.
   PubMed Web of Science ®Google Scholar
• Taromi S, Kayser G, Catusse J, et al. (2016). CXCR4 antagonists suppress small cell lung cancer progression. Oncotarget 7:85185–95.
   PubMed Web of Science ®Google Scholar
• Tsukita S, Furuse M. (2002). Claudin-based barrier in simple and stratified cellular sheets. Curr Opin Cell Biol 14:531–6.
   PubMed Web of Science ®Google Scholar
• Upadhyay RK. (2014). Drug delivery systems, CNS protection, and the blood brain barrier. Biomed Res Int 2014:37–73.
   Web of Science ®Google Scholar
• Wang Q, Luo W, Zheng W, et al. (2007). Iron supplement prevents lead-induced disruption of the blood–brain barrier during rat development. Toxicol Appl Pharm 219:33–41.
   PubMed Web of Science ®Google Scholar
• Wang S, Meng Y, Li C, et al. (2015). Receptor-mediated drug delivery systems targeting to glioma. Nanomaterials Basel 6:3–18.
   Web of Science ®Google Scholar
• Warshawsky I, Broze GJ, Schwartz AL. (1994). The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor. Proc Natl Acad Sci USA 91:6664–8.
   PubMed Web of Science ®Google Scholar
• Wei X, Chen X, Ying M, et al. (2014a). Brain tumor-targeted drug delivery strategies. Acta Pharm Sin B 4:193–201.
   PubMed Web of Science ®Google Scholar
• Wei X, Zhan C, Chen X, et al. (2014b). Retro-inverso isomer of angiopep-2: a stable d-peptide ligand inspires brain-targeted drug delivery. Mol Pharm 11:3261–8.
   PubMed Web of Science ®Google Scholar
• Wei X, Zhan C, Shen Q, et al. (2015). A D-peptide ligand of nicotine acetylcholine receptors for brain-targeted drug delivery. Angew Chem Int Edit 54:3023–7.
   PubMed Web of Science ®Google Scholar
• Wolburg H, Lippoldt A, Ebnet K. (2002). Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol 38:323–37.
   PubMed Web of Science ®Google Scholar
• Xiang Y, Liang L, Wang X, et al. (2011). Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes. J Control Release 152:402–10.
   PubMed Web of Science ®Google Scholar
• Xiao H, Deng M, Yang B, et al. (2017). Role of glycogen synthase kinase 3 in ischemia-induced blood-brain barrier disruption in aged female rats. J Neurochem 142:194–203.
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Ikeda K, Ohshima K, et al. (1997). Increased expression of low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor in human malignant astrocytomas. Cancer Res 57:2799–805.
   PubMed Web of Science ®Google Scholar
• Yi HX, Wu J, Du YZ, et al. (2015). Effect of anionic PEGylated polypeptide on gene transfection mediated by glycolipid conjugate micelles. Mol Pharmaceutics 12:1072–83.
   PubMed Web of Science ®Google Scholar
• Ying X, Wen H, Lu WL, et al. (2010). Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J Control Release 141:183–92.
   PubMed Web of Science ®Google Scholar
• Zhao MD, Sun YM, Fu GF, et al. (2012). Gene therapy of endometriosis introduced by polymeric micelles with glycolipid-like structure. Biomaterials 33:634–43.
   PubMed Web of Science ®Google Scholar
• Zlokovic BV. (2008). The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57:178–201.
   PubMed Web of Science ®Google Scholar
• Zong T, Mei L, Gao H, et al. (2014). Synergistic dual-ligand doxorubicin liposomes improve targeting and therapeutic efficacy of brain glioma in animals. Mol Pharmaceutics 11:2346–57.
   PubMed Web of Science ®Google Scholar